Arcellx, Inc. ACLX
We take great care to ensure that the data presented and summarized in this overview for Arcellx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACLX
View all-
Paradigm Biocapital Advisors LP New York, NY4MShares$354 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$344 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$332 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$311 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$218 Million0.0% of portfolio
-
Sr One Capital Management, LP2.35MShares$208 Million66.33% of portfolio
-
Janus Henderson Group PLC London, X02.01MShares$178 Million0.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.9MShares$168 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA1.85MShares$164 Million2.16% of portfolio
-
State Street Corp Boston, MA1.54MShares$137 Million0.01% of portfolio
Latest Institutional Activity in ACLX
Top Purchases
Top Sells
About ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Insider Transactions at ACLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
$24,000
$8.66 P/Share
|
|
Nov 15
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,761
-70.42%
|
$158,490
$90.93 P/Share
|
|
Nov 12
2024
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$159,000
$106.33 P/Share
|
|
Nov 12
2024
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
Nov 11
2024
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
15,238
-90.14%
|
$1,615,228
$106.3 P/Share
|
|
Nov 11
2024
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
15,238
+50.0%
|
$228,570
$15.0 P/Share
|
|
Nov 08
2024
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
33,763
-41.64%
|
$3,410,063
$101.88 P/Share
|
|
Nov 08
2024
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
33,763
+46.65%
|
$337,630
$10.83 P/Share
|
|
Nov 08
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,354
-47.32%
|
$1,247,754
$101.29 P/Share
|
|
Nov 08
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,200
+33.78%
|
$57,600
$8.66 P/Share
|
|
Nov 07
2024
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
8,478
-100.0%
|
$839,322
$99.3 P/Share
|
|
Nov 07
2024
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,478
+50.0%
|
$50,868
$6.66 P/Share
|
|
Oct 22
2024
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$133,500
$89.69 P/Share
|
|
Oct 22
2024
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
Oct 01
2024
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$123,000
$82.24 P/Share
|
|
Oct 01
2024
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
Sep 17
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
15,000
-42.21%
|
$1,155,000
$77.7 P/Share
|
|
Sep 17
2024
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+40.63%
|
$120,000
$8.66 P/Share
|
|
Sep 10
2024
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$111,000
$74.41 P/Share
|
|
Sep 10
2024
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 604K shares |
|---|
| Open market or private sale | 1.6M shares |
|---|